LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Rated "Hold" by Sell-Side Analysts

Key Points

• Analysts broadly rate LeMaitre Vascular “Hold.” Five of nine covering firms recommend holding the stock, while four rate it a buy; the average 12-month price target is $110.60.
• The company’s latest quarterly results fell short of expectations, with EPS of $0.74 versus the $0.81 consensus and revenue of $70.38 million versus $71.47 million expected. Revenue nevertheless increased 9.6% year over year.
• LeMaitre Vascular pays a quarterly dividend of $0.25 per share, equivalent to a $1.00 annualized payout and a 1.2% yield, while institutional investors own 84.64% of outstanding shares.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has been assigned an average recommendation of "Hold" from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $110.60.

A number of equities research analysts recently commented on the stock. Wells Fargo & Company dropped their price objective on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating on the stock in a report on Wednesday, August 5th. Zacks Research lowered shares of LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Citigroup reiterated a "market outperform" rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Weiss Ratings raised LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th. Finally, Wall Street Zen downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st.

LeMaitre Vascular Stock Up 1.3%

NASDAQ:LMAT opened at $82.62 on Thursday. LeMaitre Vascular has a 1 year low of $78.22 and a 1 year high of $118.01. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of 28.99, a PEG ratio of 2.35 and a beta of 0.48. The stock has a 50-day moving average price of $80.87 and a two-hundred day moving average price of $94.46.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts' consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%. The business had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. During the same period in the prior year, the business earned $0.60 EPS. The company's revenue for the quarter was up 9.6% compared to the same quarter last year. As a group, equities analysts expect that LeMaitre Vascular will post 2.89 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Thursday, August 20th. LeMaitre Vascular's dividend payout ratio is currently 35.09%.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. Pictet Asset Management Holding SA grew its stake in shares of LeMaitre Vascular by 5.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier's stock worth $356,000 after acquiring an additional 169 shares in the last quarter. Sound Income Strategies LLC lifted its position in shares of LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC bought a new stake in shares of LeMaitre Vascular in the first quarter worth $32,000. EverSource Wealth Advisors LLC lifted its position in shares of LeMaitre Vascular by 28.4% in the first quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier's stock worth $152,000 after purchasing an additional 308 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV boosted its holdings in LeMaitre Vascular by 1.7% during the first quarter. Nations Financial Group Inc. IA ADV now owns 25,811 shares of the medical instruments supplier's stock worth $2,818,000 after purchasing an additional 419 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company that develops, manufactures and markets products used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on blood vessels outside the heart and brain, including procedures involving the carotid, lower-extremity and aortic vascular systems.

The company's product portfolio includes biologic and synthetic vascular grafts, angioplasty and thrombectomy catheters, valvulotomes, carotid shunts, vascular clamps and other devices used in open and minimally invasive vascular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.